Source Genomics, a part of the Source BioScience group, announced the launch of its expanded portfolio of biomarker-driven tests, designed to enhance clinical decision-making and improve patient access to precision care. This milestone reinforces the company’s commitment to advancing oncology diagnostics and supporting clinicians in delivering tailored treatment strategies.

As a trusted laboratory partner, Source Genomics provides healthcare professionals with cutting-edge tools to integrate innovative diagnostics into routine practice. The new offering supports the full continuum of care, from early detection and patient risk stratification to post-diagnostic treatment guidance.

• Precision testing – Advanced biomarker assays designed to inform and refine oncology care pathways.
• Trusted partnership – Reliable laboratory support to empower clinicians and healthcare providers.
• Better access for patients – Expanding the reach of precision diagnostics to improve outcomes and equity of care.

This launch follows the recent acquisition of Cambridge Clinical Laboratories, further strengthening Source Genomics’ capabilities and expanding its footprint in precision oncology. Together with Source LDPath, Source BioScience is building an integrated ecosystem that combines advanced testing with digital pathology expertise, driving innovation across the cancer care pathway.

Watch this short video to learn more about Source Genomics’ vision for the future of precision oncology.